VX-765 ameliorates renal injury and fibrosis in diabetes by regulating caspase-1-mediated pyroptosis and inflammation

J Diabetes Investig. 2022 Jan;13(1):22-33. doi: 10.1111/jdi.13660. Epub 2021 Oct 12.

Abstract

Introduction: As a lytic inflammatory cell death, pyroptosis has been recently described but has not been unequivocally elucidated in diabetic nephropathy (DN). VX-765 is a safe and effective inhibitor of caspase-1, that was well tolerated in a phase II clinical trial in patients with epilepsy, but its application in DN is still undefined.

Materials and methods: Immunoblot, co-immunoprecipitation, confocal microscope and flow cytometry were used to analyze the effects of glucose on pyroptosis in renal tubular epithelia (HK-2). In vitro, selective caspase-1 inhibitors VX-765 and Z-YVAD-FMK were administered. Pyroptosis and fibrogenesis were determined by immunoblot, ELISA, cytotoxicity assay and flow cytometry. In vivo, diabetic mice were administered with 100 mg/kg VX-765. Renal function, pathological changes, and the expressions of NLRC4, GSDMD, IL-1β, collagen I, fibronectin and CD45 in renal cortex were evaluated.

Results: We identified NLRC4 as a sensor for caspase-1 activation. Moreover, we provided morphological and molecular evidence for pyroptosis in glucose-stressed tubular cells, including ballooned cell membrane, caspase-1 immunoreactivity, GSDMD cleavage, and the release of inflammatory cytokine and cellular contents. All these effects were prevented by treatment with VX-765 or Z-YVAD-FMK, confirming that caspase-1 effectively regulates the occurrence of pyroptosis in HK-2 cells. In vivo, treatment of diabetic animals with VX-765 ameliorated renal function, suppressed inflammatory cell infiltration and pyroptosis-associated protein expression, and mitigated tubulointerstitial fibrosis.

Conclusions: This work revealed that caspase-1-mediated pyroptosis drives renal inflammation and fibrosis in diabetes. Our results are the first demonstration of VX-765 representing a promising therapeutic opportunity for alleviating the progression of DN.

Keywords: Caspase-1; Diabetic nephropathy; GSDMD; Inflammation; Pyroptosis; VX-765.

MeSH terms

  • Animals
  • Caspase 1 / metabolism
  • Cell Culture Techniques
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / pathology
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / pathology
  • Dipeptides / pharmacology*
  • Fibrosis
  • Glucose / pharmacology
  • Humans
  • Inflammation
  • Kidney / pathology*
  • Kidney Tubules / drug effects
  • Kidney Tubules / pathology
  • Male
  • Mice
  • Pyroptosis / drug effects*
  • para-Aminobenzoates / pharmacology*

Substances

  • Dipeptides
  • para-Aminobenzoates
  • belnacasan
  • Caspase 1
  • Glucose